3 results
Approved WMORecruiting
Primary objectives: 1. Safety 2. Practical feasibility Secondary objectives: 1. angiographic patency rate before PCI 2. Cumulative ST-segment resolution. 3. myocardial infarct characteristics 4. Myocardial perfusion on contrast echocardiography 5.…
Approved WMORecruiting
The hypothesis is that the amivantamab and lazertinib combination (Arm A) will demonstrate superior PFS compared with single-agent osimertinib (Arm B).
Approved WMORecruiting
• to assess the efficacy of the sequential combination strategy of front-line afatinib-chemo, followed by a treatment with osimertinib-chemo in those patients that develop a T790M mutation as a mechanism of resistance.